Visceral leishmaniasis and arsenic: An ancient poison contributing to antimonial treatment failure in the Indian subcontinent?

PLoS Neglected Tropical Diseases

Volumn 5, Issue 9, 2011, Pages

  Perry, Meghan R ^a   Wyllie, Susan ^a   Prajapati, Vijay Kumar ^b   Feldmann, Joerg ^c   Sundar, Shyam ^b   Boelaert, Marleen ^d   Fairlamb, Alan H ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b BANARAS HINDU UNIVERSITY   (India)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; ANTIMONY DERIVATIVE; AQUAGLYCEROPORIN; ARSENIC; ARSENIC ACID; ARSENIC TRIOXIDE; CHLOROQUINE; GROUND WATER; MILTEFOSINE; ANTIMONY; ANTIPROTOZOAL AGENT; POISON;

ARSENIC POISONING; ARTICLE; CLINICAL FEATURE; CLINICAL PRACTICE; DISEASE ACTIVITY; DISEASE TRANSMISSION; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG RESISTANCE; DRUG TREATMENT FAILURE; GEOGRAPHIC DISTRIBUTION; HEALTH PROGRAM; HUMAN; INDIA; INFECTION CONTROL; INFECTION RISK; LIVER BIOPSY; NONHUMAN; RELAPSE; THERAPY EFFECT; TREATMENT DURATION; VIRUS RESISTANCE; VISCERAL LEISHMANIASIS; WATER ANALYSIS; WATER CONTAMINATION; DRUG EFFECT; LEISHMANIA; LEISHMANIA DONOVANI; LEISHMANIA INFANTUM; METABOLISM; TREATMENT FAILURE;

ANTIMONY; ANTIPROTOZOAL AGENTS; ARSENIC; DRUG RESISTANCE; HUMANS; INDIA; LEISHMANIA; LEISHMANIA DONOVANI; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL; POISONS; TREATMENT FAILURE;

EID: 80053445928     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001227     Document Type: Article

References (46)

1. Guerin PJ, Olliaro P, Sundar S, Boelaert M, Croft SL, Desjeux P, Wasunna MK, Bryceson AD, (2002) Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis 2: 494-501.
2. Olliaro PL, Guerin PJ, Gerstl S, Haaskjold AA, Rottingen JA, Sundar S, (2005) Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infect Dis 5: 763-774.
3. Lira R, Sundar S, Makharia A, Kenney R, Gam A, Saraiva E, Sacks D, (1999) Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J Infect Dis 180: 564-567.
4. Croft SL, Sundar S, Fairlamb AH, (2006) Drug resistance in Leishmaniasis. Clin Microbiol Rev 19: 111-126.
5. Hasker E, Singh SP, Malaviya P, Singh RP, Shankar R, Boelaert M, Sundar S, (2010) Management of visceral leishmaniasis in rural primary health care services in Bihar, India. Trop Med Int Health 15: 55-62.
6. Ravenscroft P, Brammer H, Richards K, (2009) Arsenic pollution: a global synthesis. Chichester John Wiley & Sons.
7. Yan S, Jin L, Sun H, (2005) 51Sb antimony in medicine. In: Gielen M, Tiekink ERT, editors. Metallotherapeutic drugs & metal-based diagnostic agents, The use of metals in medicine pp. 441-461.
8. Dey S, Papadopoulou B, Haimer A, Roy G, Grondin K, Dou D, Rosen BP, Ouellette M, (1994) High level arsenite resistance in Leishmania tarentolae is mediated by an active extrusion system. Mol Biochem Parasitol 67: 49-57.
9. Mazumder DNG, (2005) Effect of chronic intake of arsenic-contaminated water on liver. Toxicol Appl Pharmacol 206: 169-175.
10. Herwaldt BL, (1999) Leishmaniasis. Lancet 354: 1191-1199.
11. Sundar S, Mondal D, Rijal S, Bhattacharya S, Ghalib H, Kroeger A, Boelaert M, Desjeux P, Richter-Airijoki H, Harms G, (2008) Implementation research to support the initiative on the elimination of kala azar from Bangladesh, India and Nepal-the challenges for diagnosis and treatment. Trop Med Int Health 13: 2-5.
12. Singh RK, Pandey HP, Sundar S, (2006) Visceral leishmaniasis (kala-azar): challenges ahead. Indian J Med Res 123: 331-344.
13. Mondal D, Singh SP, Kumar N, Joshi A, Sundar S, Das P, Siddhivinayak H, Kroeger A, Boelaert M, (2009) Visceral leishmaniasis elimination programme in India, Bangladesh, and Nepal: reshaping the case finding/case management strategy. PLoS Negl Trop Dis 3: e355 doi:10.1371/journal.pntd.0000355.
14. Peters W, (1981) The treatment of Kala-Azar- new approaches to an old problem. Indian J Med Res 73: 1-18.
15. Thakur CP, (1984) Epidemiological, clinical and therapeutic features of Bihar kala-azar (including post kala-azar dermal leishmaniasis). Trans R Soc Trop Med Hyg 78: 391-398.
16. Thakur CP, Kumar M, Kumar P, Mishra BN, Pandey AK, (1988) Rationalisation of regimens of treatment of kala-azar with sodium stibogluconate in India: a randomised study. Br Med J (Clin Res Ed) 296: 1557-1561.
17. Chakraborti D, Mukherjee SC, Pati S, Sengupta MK, Rahman MM, Chowdhury UK, Lodh D, Chanda CR, Chakraborty AK, Basul GK, (2003) Arsenic groundwater contamination in Middle Ganga Plain, Bihar, India: a future danger? Environ Health Perspect 111: 1194-1201.
18. Rijal S, Chappuis F, Singh R, Bovier PA, Acharya P, Karki BMS, Das ML, Desjeux P, Loutan L, Koirala S, (2003) Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline. Trans R Soc Trop Med Hyg 97: 350-354.
19. Mubayi A, Castillo-Chavez C, Chowell G, Kribs-Zaleta C, Siddiqui NA, Kumar N, Das P, (2010) Transmission dynamics and underreporting of Kala-azar in the Indian state of Bihar. J Theor Biol 262: 177-185.
20. Payne D, (1988) Did medicated salt hasten the spread of chloroquine resistance in Plasmodium falciparum. Parasitol Today 4: 112-115.
21. Deshingkar P, Kumar S, Chobey HK, Kumar D, (2006) The role of migration and remittances in promoting livelihoods in Bihar. London Overseas Development Institute.
22. Vanaerschot M, Maes I, Ouakad M, Adaui V, Maes L, De Doncker S, Rijal S, Chappuis F, Dujardin JC, Decuypere S, (2010) Linking in vitro and in vivo survival of clinical Leishmania donovani strains. PLoS ONE 5: e12211 doi:10.1371/journal.pone.0012211.
23. El Fadili K, Messier N, Leprohon P, Roy G, Guimond C, Trudel N, Saravia NG, Pavadopoulou B, Legare D, Ouellette M, (2005) Role of the ABC transporter MRPA (PGPA) in antimony resistance in Leishmania infantum axenic and intracellular amastigotes. Antimicrob Agents Chemother 49: 1988-1993.
24. Haimeur A, Brochu C, Genest PA, Papadopoulou B, Ouellette M, (2000) Amplification of the ABC transporter gene PGPA and increased trypanothione levels in potassium antimonyl tartrate (SbIII) resistant Leishmania tarentolae. Mol Biochem Parasitol 108: 131-135.
25. Bern C, Chowdhury R, (2006) The epidemiology of visceral leishmaniasis in Bangladesh: prospects for improved control. Indian J Med Res 123: 275-288.
26. Argos M, Kalra T, Rathouz PJ, Chen Y, Pierce B, Parvez F, Islam T, Ahmed A, Rakibuz-Zaman M, Hasan R, Sarwar G, Slavkovich V, van Geen A, Graziano J, Ahsan H, (2010) Arsenic exposure from drinking water, and all-cause and chronic-disease mortalities in Bangladesh (HEALS): a prospective cohort study. Lancet 376: 252-258.
27. Sohel N, Persson LA, Rahman M, Streatfield PK, Yunus M, Ekstrom EC, Vahter M, (2009) Arsenic in drinking water and adult mortality a population-based cohort study in rural Bangladesh. Epidemiology 20: 824-830.
28. Vahter M, (1999) Methylation of inorganic arsenic in different mammalian species and population groups. Sci Prog 82: 69-88.
29. Raab A, Feldmann J, (2005) Arsenic speciation in hair extracts. Anal Bioanal Chem 381: 332-338.
30. Das S, Santra A, Lahiri S, Mazumder DNG, (2005) Implications of oxidative stress and hepatic cytokine (TNF-alpha and IL-6) response in the pathogenesis of hepatic collagenesis in chronic arsenic toxicity. Toxicol Appl Pharmacol 204: 18-26.
31. Mukhopadhyay R, Rosen BP, Pung LT, Silver S, (2002) Microbial arsenic: from geocycles to genes and enzymes. FEMS Microbiol Rev 26: 311-325.
32. Berman JD, Gallalee JV, Hansen BD, (1987) Leishmania mexicana uptake of sodium stibogluconate (pentostam) and pentamidine by parasite and macrophages. Exp Parasitol 64: 127-131.
33. Bhattacharjee H, Carbrey J, Rosen BP, Mukhopadhyay R, (2004) Drug uptake and pharmacological modulation of drug sensitivity in leukemia by AQP9. Biochem Biophys Res Commun 322: 836-841.
34. Dey S, Ouellette M, Lightbody J, Papadopoulou B, Rosen BP, (1996) An ATP-dependent As(III)-glutathione transport system in membrane vesicles of Leishmania tarentolae. Proc Natl Acad Sci U S A 93: 2192-2197.
35. Légaré D, Richard D, Mukhopadhyay R, Stierhof YD, Rosen BP, Haimeur A, Papadopoulou B, Ouellette M, (2001) The Leishmania ATP-binding cassette protein PGPA is an intracellular metal-thiol transporter ATPase. J Biol Chem 276: 26301-26307.
36. Ashutosh, Sundar S, Goyal N, (2007) Molecular mechanisms of antimony resistance in Leishmania. J Med Microbiol 56: 143-153.
37. Mittal MK, Rai S, Ravinder A, Gupta S, Sundar S, Goyal N, (2007) Characterization of natural antimony resistance in Leishmania donovani isolates. Am J Trop Med Hyg 76: 681-688.
38. Wyllie S, Cunningham ML, Fairlamb AH, (2004) Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani. J Biol Chem 279: 39925-39932.
39. Brochu C, Wang JY, Roy G, Messier N, Wang XY, Saravia NG, Ouellette M, (2003) Antimony uptake systems in the protozoan parasite Leishmania and accumulation differences in antimony-resistant parasites. Antimicrob Agents Chemother 47: 3073-3079.
40. Wyllie S, Vickers TJ, Fairlamb AH, (2008) Roles of trypanothione S-transferase and tryparedoxin peroxidase in resistance to antimonials. Antimicrob Agents Chemother 52: 1359-1365.
41. Wyllie S, Mandal G, Singh N, Sundar S, Fairlamb AH, Chatterjee M, (2010) Elevated levels of tryparedoxin peroxidase in antimony unresponsive Leishmania donovani field isolates. Mol Biochem Parasitol 173: 162-164.
42. Rijal S, Yardley V, Chappuis F, Decuypere S, Khanal B, Singh R, Boelaert M, De DS, Croft S, Dujardin JC, (2007) Antimonial treatment of visceral leishmaniasis: are current in vitro susceptibility assays adequate for prognosis of in vivo therapy outcome? Microbes Infect 9: 529-535.
43. Seifert K, Escobar P, Croft SL, (2010) In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependent. J Antimicrob Chemother 65: 508-511.
44. Thakur CP, Narayan S, Ranjan A, (2004) Epidemiological, clinical & pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India. Indian Journal of Medical Research 120: 166-172.
45. Sundar S, (2001) Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 6: 849-854.
46. Central Ground Water Board (2010) Groundwater quality in shallow aquifers of India.